– Additional monitoring data helped clinicians optimize drug therapy in nearly onethird of study patients –
PORTSMOUTH, NH USA, LONDON, UK, MELBOURNE, Australia, and MOUNTAIN VIEW, CA USA February 4, 2019 – Global Kinetics Corporation Ltd., in conjunction with the Parkinson’s Institute and Clinical Center, today announced the publication of a joint study in the Journal of Parkinson’s Disease. Study authors concluded that the Personal KinetiGraph® (PKG®), a wearable device that precisely monitors, quantifies, and reports movement symptoms in patients with Parkinson’s disease (PD), provided additional information beyond that which is typically captured during routine clinical visits. This new data was significant enough to change the medical management of nearly one-third of the participating patients. The pre-press online version of the article is available at https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd181373.
“The Parkinson’s Institute and Clinical Center is at the forefront of evaluating new technologies and therapeutics, and is committed to providing the highest quality of care for people with movement disorders. The wearable PKG technology provides objective measurements which allow us to further deliver the highly individualized care that a patient deserves,” said Carrolee Barlow, M.D., Ph.D., former Chief Executive Officer of the Parkinson’s Institute and Clinical Center and an author on the study.
Currently, it is difficult to track a patient’s motor symptoms when the patient is at home. Global Kinetics’ PKG is the first FDA-cleared technology to provide continuous quantitative data on movement disorder symptoms including tremor, bradykinesia (slow movement) and dyskinesia (abnormal or impaired movement) in a non-clinical setting. The wearable technology is worn at home by patients for several days to help objectively monitor motor symptoms and the information is then transmitted to their physician for review during their next clinical visit.
The study, reported in the Journal of Parkinson’s Disease, was conducted at the Parkinson’s Institute and Clinical Center from December 2015 through July 2016. It was comprised of a survey completed by four movement disorder specialists to whom PKG data was available for four categories of patients: patients visiting the clinic for the first time, patients with fluctuations in Parkinson’s symptoms, patients with an unclear Parkinson’s symptom history and patients considering advanced therapy. For each patient visit, the survey assessed whether or not the PKG provided additional information beyond what could be gathered through physician examination and patient-reported symptoms. An evaluation of the impact of the additional information on changes to clinical management was assessed.
Of the 112 surveys conducted in the study, 41% indicated that the PKG provided additional information to the physician. Of these surveys, 78% showed that the data resulted in changes to the patient’s treatment plan. The most common new piece of information from the PKG resulting in treatment changes was precise information on when the patient was not adequately treated, referred to as “daily OFF times” (50%).
John Schellhorn, CEO of Global Kinetics Corporation said, “These results demonstrate the real-world clinical benefits that PKG can provide to patients and clinicians in their continuing effort to optimize Parkinson’s therapy, and manage symptoms effectively. In the absence of standardized objective measures for assessing and managing PD, we believe that PKG has the potential to transform the care and outcomes of patients living with the daily challenges of this disease. The results of this study support the use of PKG as an important tool for individualizing therapy to best meet each patient’s unique needs.”
About Global Kinetics Corporation Ltd.
Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialise its lead product, Personal KinetiGraph® (PKG). Developed in conjunction with the worldrenowned Florey Institute of Neuroscience & Mental Health in Melbourne, Australia, PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s. To date, Global Kinetics has supported clinical decisions for doctors who treat patients with Parkinson’s disease across 17 countries with more than 3,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis, MN, and Portsmouth, NH, USA.
For more information, visit: www.globalkineticscorporation.com
Follow our LinkedIn updates:
About Parkinson’s Institute and Clinical Center.
The Parkinson’s Institute and Clinical Center is at the forefront of patient care and therapy development. We are the nation’s only Institute that provides patient care, and clinical research in one integrated model. Our unique freestanding organization and strategic partnerships directly connect research to patient care – from the “bench to bedside.” For 30 years, our team of epidemiologists, physicians, scientists, and therapists, have been at the forefront of every clinical and scientific discovery in the field of Parkinson’s research.
Since our inception, patients have come from 38 states and many foreign countries for their care. We have managed more than 125 clinical research trials, medically evaluating more than 90 different drugs and therapies for Parkinson’s. The result: our Institute has been directly involved in bringing every Parkinson’s drug currently available to the market. The Institute is at the forefront of discovering and developing the latest, most innovative treatments and therapies for people living with Parkinson’s.
For more information visit www.thepi.org or call 650-770-0201.
Chantal Beaudry / Amy Feldman
+1 (646) 871-8480 / +1 (212) 867-1779